Substance with sedative effect

Details Substance with sedative effect Substance with sedative effect

2006-08-08

2006-08-08

Kim, Vickie (Department: 1618)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C514S456000

Reexamination Certificate

active

07087640

ABSTRACT:
A substance with sedative effect comprises a therapeutically effective amount of a gamma-pyrone such as comenic acid, meconic acid, chelidonic acid, and alike in a pharmaceutically acceptable carrier. When administered at a daily dosage of between 5 and 200 mg of active ingredient per kilogram of a body weight of a patient, the substance can be used to treat various neurotic disorders such as insomnia, anxiety, neurosis, depression as well as withdrawal symptoms for drug addiction patients, especially for patients addicted to opioid-based drugs. The substance can be delivered in a number of ways of systemic administration of a pharmaceutical agent including oral, parenteral, transdermal, and transmucosal administration. For drug addicted patients, the preferred method of administration involves a subcutaneous implant providing a continuous release of an active ingredient at an effective daily rate over the entire treatment period ranging from 5 to 30 days, and preferably from 13 to 20 days.

REFERENCES:
patent: 1782111 (1930-11-01), Adams
patent: 1796977 (1931-03-01), Bailey
patent: 3706831 (1972-12-01), Plotnikoff
patent: 3710795 (1973-01-01), Higuchi
patent: 3742951 (1973-07-01), Zaffaroni
patent: 3797494 (1974-03-01), Zaffaroni
patent: 4115567 (1978-09-01), Doria
patent: 4117161 (1978-09-01), Pozuelo
patent: 4124715 (1978-11-01), Pozuelo
patent: 4198426 (1980-04-01), Philipp
patent: 4221890 (1980-09-01), Dimmick
patent: 4276890 (1981-07-01), Fichera
patent: 4311691 (1982-01-01), Fichera
patent: 4325952 (1982-04-01), Silvestrini
patent: 4568343 (1986-02-01), Leeper
patent: 4575502 (1986-03-01), Hider
patent: 4696818 (1987-09-01), Kim
patent: 4786653 (1988-11-01), Golwyn
patent: 4788189 (1988-11-01), Glazer
patent: 4866052 (1989-09-01), Hider et al.
patent: 5219858 (1993-06-01), Parnell
patent: 5411985 (1995-05-01), Bills
patent: 5470873 (1995-11-01), Yoon
patent: 5506268 (1996-04-01), Balandrin
patent: 5589182 (1996-12-01), Tashiro et al.
patent: 5646179 (1997-07-01), Muller-Kuhrt
patent: 5888993 (1999-03-01), McNell
patent: 2003/0211180 (2003-11-01), Cheng et al.
patent: 53-18739 (1978-02-01), None
patent: 2178303 (2002-01-01), None
patent: WO 92/13850 (1992-08-01), None
patent: WO9714414 (1997-04-01), None
patent: WO9907413 (1999-02-01), None
Napoli V., Treatment of postoperative pain in foot surgery., Database EMBASE, AN:96268834 (abstract only) Chirurgia del Piede, 1996, vol. 20(No. 1), pp. 39-42.
Durg information, Opium Poppy, Herbs2000.com,Database from GOOGLE.com, (http://herbs2000.com/herbs/herbs—poppy—opium.htm.
Drug information, POPP, white, Botanical.com, Data base form GOOGLE. com.
ICTFM base, drug information on Papaver Somniferm L., Database from GOOGLE.com.
Felter HW, Lloyd Ju Opium (U.S.P.)—Opium, from King's American Dispensatory, 1898. Printout of the Internet site www.ibiblio.org, 17 pages, Nov. 20, 2003.
Krylov BV, Derbenev AV, Podzorova SA, et al. Morphine decreases the voltage sensitivity of slow sodium channels. Neuroscience and Behavioral Physiology vol. 30, No. 4, 2000, pp. 431-439, Kluwer Academic/Plenum Publishers.
Plakhova VB Shchegolev BF, Rogachevskii IV et al. A possible molecular mechanism for the interaction of defensin with the sensory neuron membrane. Neuroscience and Behavioral Physiology vol. 32, No. 4, 2002, pp. 409-415, Plenum Publishing Corp.
Krylov BV, Bagraev NT, Klyachkin Le et al. Chemical and infrared light induced effects on the voltage sensitivity of slow sodium channel. Proceedings of SPAS, vol. 4, pp. A38-A39, Jun. 12-17, 2000, St. Peterburg, RUSSIA.
Krylov BV, Podzorova SA, Vilin YY. Inactivation kinetics of sensory neuron sodium channels depend on the type of hydrogen ion buffer. Neuroscience and Behavioral Physiology vol. 28, No. 1, 1998, pp.65-71, Plenum Publishing Corp.
Derbenev AV, Krylov BV, Shurygin AY. Effects of meconic and comenic acids on slow sodium channels of secondary neurons. Membrane Cell Biology, 2000, vol. 13(3), pp. 379-387.
Hunt SP Mantyh PW. The molecular dynamics of pain control. Nature reviews. Neuroscience. vol. 2, Feb. 2001, pp. 83-91.
Palmer AM, Carter N. The role of sodium channels in disease . The Newsletter for the Society for Medicines Research. Jan. 2002, vol. 8, Issue 1, pp. 1-14.
Jensen TS, Gottrup H, Kasch H et al. Has basic research contributed to chronic pain treatment? Acta Anaesthesiologica Scandinavica, 2001, 45, pp. 1128-1135.
Xie Z. Ouabain interaction with cardiac Na/K-ATPase reveals that the enzyme can act as a pump and as a signal transducer. Cellular and Molecular Biology, 2001, 47(2), pp. 383-390.
Krylov BV et al. Ethanol modifyes rat sensory neuron sodium channels. Russian Journal of Physiology, 1999, 85-N-1, pp. 110-118. In Russian with English abstract.
Plakhova VB, Sabanov VS et al. Probable molecular mechanisms of slow sodium channels gating machinery . . . Sensory Systems, vol. 14, No. 1, 2000, pp. 48-59. Published in Russian with English abstract.
Katina IE, Shchegolev BF, Zadina JE, McKee ML, Krylov BV. Endomorphins inhibit currents through voltage-dependent sodium channels. Sensory Systems, vol. 17, No. 1, 2003, pp. 1-17. Published in Russian with English abstract.

Affiliated with

Also associated with

Rating

Substance with sedative effect does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Substance with sedative effect, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substance with sedative effect will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3659272